期刊文献+

晚期卵巢癌新辅助化疗的Meta分析 被引量:6

Neoadjuvant chemotherapy in advanced ovarian cancer:a Meta analysis of randomized controlled trials
下载PDF
导出
摘要 目的:评价新辅助化疗对晚期卵巢癌患者总生存期及无进展生存期的影响,探讨新辅助化疗在晚期卵巢癌的应用价值。方法:计算机检索PubMed数据库、Med-line数据库、EMbas数据库、Cochrane Library数据库、万方数据库、中国学术文献总库(CNKI)、中国生物医学文献数据库(CBM),手工检索《中华妇产科杂志》,《中国实用妇科与产科杂志》,《实用妇产科杂志》,《生殖与避孕》,《现代妇产科进展》5本妇产科杂志。语言种类为中文和英文,网上检索时间不限。试验组行新辅助化疗,即以铂类为基础的化疗后行细胞减灭术;对照组行传统治疗,即细胞减灭术后行规范性化疗。结果:共纳入3篇文献,提取数据后,Review Manager5.0软件进行Meta分析,两组的总生存期合并后的RR值为0.96(95%CI,0.90~1.03),两组的无进展生存期合并后的RR值为1.00(95%Cl 0.93~1.09),森林图菱形均与垂直线相交。结论:新辅助化疗并未改善晚期卵巢癌患者的预后。 Objective:To evaluate whether neoadjuvant chemotherapy will improve progession free survival(PFS) and overall survival(OS) in advanced ovarian cancer patients.Methods:We search PubMed database,Medline database,EMbas database,Cochrane Library,WANFANG database,CNKI and CBM in the internet.We also hand-search 5 journals of Obstetrics and Gynecology(Chinese Journal of Obstetrics and Gynecology,Chinese Journal of Practical Gynecology and Obstetrics,Journal of Practical Obstetrics and Gynecology,Reproduction and Contraception,Progress in Obstetrics and Gynecology).The experimental group accepted platinum-based adjuvant chemotherapy before cytoreductive surgery and the control group accepted primary cytoreductive surgery following adjuvant chemotherapy.Results:Totally 3 articles were included.Meta-analysis on the selected literature was processed by Revman 5.0.According to the results of fixed-effect model,the RR of OS was 0.96(95%CI,0.90~1.03).Because there was heterogeneity in PFS,the result adopt random-effect model,the RR of PFS was 1.00(95%Cl 0.93~1.09).Conclusion:Neoadjuvant chemotherapy don't improve the outcome for advanced ovarian cancer.
出处 《现代妇产科进展》 CSCD 2013年第1期28-31,共4页 Progress in Obstetrics and Gynecology
关键词 卵巢肿瘤 诱导化疗 专题综合分析 系统分析 化学疗法 辅助 随机对照试验 Ovarian neoplasms Induction chemotherapy Meta-analysis as topic Systems analysis Chemotherapy adjuvant Randomized controlled trial
  • 相关文献

参考文献23

  • 1du Bois A,Quinn M,Thigpen T. 2004 consensus statemeuts on the management of ovarian cancer:final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)[J].Annals of Oncology,2005,((Suppl) 8):viii7-viii12.
  • 2Jacob JH,Gershenson DM,Morris M. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer[J].Gynecologic Oncology,1991,(02):146-150.
  • 3Kayikcioglu F,Kose MF,Boran N. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma[J].International Journal of Gynecological Cancer,2001,(06):466-470.
  • 4Loizzi V,Cormio G,Resta L. Neoadjuvant chemotherapy in advanced ovarian cancer:a case-control study[J].International Journal of Gynecological Cancer,2005,(02):217-223.
  • 5Morice P,Dubernard G,Rey A. Results of interv al debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer[J].Journal of the American College of Surgeons,2003,(06):955-963.
  • 6Schwartz PE,Rutherford TJ,Chambers JT. Neoadjuvant chemotherapy for advanced ovarian cancer:long-term survival[J].Gynecologic Oncology,1999,(01):93-99.
  • 7Ansquer Y,Leblanc E,Clough K. Neoadjuvant chemotherapy for unresectable ovarian carcinoma:a French multicenter study[J].Cancer,2001,(12):2329-2334.
  • 8Kuhn W,Rutke S,Spathe K. Neoadjuvant ohemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage ⅢC ovarian carcinoma[J].Cancer,2001,(10):2585-2591.
  • 9Shibata K,Kikkawa F,Mika M. Neoadjuvant chemotherapy for FIGO stage Ⅲ or Ⅳ ovarian cancer:Survival benefit and prognostic factors[J].International Journal of Gynecological Cancer,2003,(05):587-592.
  • 10Fanfani F,Ferrandina G,Corrado G. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage Ⅲc ovarian cancer patients[J].Oncology(Basel),2003,(04):316-322.

二级参考文献13

  • 1王晓平,王晓娟,栾汛,韩靖.新辅助化疗在晚期卵巢癌治疗中的作用[J].中国肿瘤临床,2007,34(8):465-466. 被引量:11
  • 2Angioli R,Palaia I,Zullo MA.Diagnostic open laparoscopy in the management of advanced ovarian cancer.Gynecol Oncol,2006,100(3):455-461.
  • 3Deffieux X,Castaigne D,Pomel C.Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer.Int J Gynecol Cancer,2006,16(s1):35-40.
  • 4Kuhn W,Rutke S,Spathe K,et al.Neoadjuvant chemotherapy followed by tumor dubulking prolongs survival for patients with poor prognosis in international federation of gynecology and obstetrics stage Ⅲc ovarian carcinoma.Cancer,2001,92(10):2585-2591.
  • 5Kayikcioglu F,Kose MF,Boran N,et al.Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma.Int J Gynaecol Cancer,2001,11(6):466-470.
  • 6Shimizu Y,Hasumi K.Treatment of stage Ⅲ and Ⅳ ovarian cancer is neoadjuvant chemotherapy effective.Nippon Sanka Fujinka Gakkai Zasshi,1993,45:1007-1014.
  • 7Shibata Y,Kikkawa F,Mika M,et al.Neoadjuvant chemotherapy for FIGO stage Ⅲ or Ⅳ ovarian cancer:survival benefit and prognostic factors.Int J Gynecol Cancer,2003,13:587-592.
  • 8Chwartz PE,Rutherford TJ,Chember JT,et al.Neoadjuvant chemotherapy for advanced ovarian epithelial ovarian carcinoma.Int J Gynecol Cancer,2001,11(6):93-99.
  • 9McLean KA,Shah CA,Thompson SA,et al.Ovarian cancer in the elderly:outcomes with neoadjuvant chemotherapy or primary cytoreduction.Gynecol Oncol,2010,118(1):43-46.
  • 10Hegazy MA,Hegazi RA,Elshafei MA,et al.Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma.World J Surg Oncol,2005,3(11):57.

共引文献4

同被引文献49

  • 1顾欣,娄阁,张嘉文,黄泽林.^(18)FDG-PET显像在监测卵巢癌复发和转移中的作用[J].实用肿瘤学杂志,2007,21(3):270-272. 被引量:11
  • 2Stuart GCE, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer Inter Group (GCIG) consensus statement on clinical trials in ovarian cancer. Report from the fourth ovarian canc- er consensus conference[ J]. Gynecol Cancer,2011,21 (3) : 750 - 755.
  • 3Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemo- therapy or primary surgery in stage IIIc- IV ovarian cancer[J]. New Engl Med,2010,363(9) :943 -953.
  • 4Vergot IB, De Wever I, Dec|oedt J, et al. Neoadju,Jant chem- otherapy versus primary debulking surgery in advanced o- varian cancer J ]. Semin Onco1,2000 ,27 ( 1 ) :31 - 36.
  • 5Hou JY, Kelly MG, Yu H, et al. neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease [ J ]. Gyneco- logic Oncology,2007,105 ( 1 ) ;211 - 217.
  • 6Petria L, Hogdall E, Christensen IJ, et al. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer[ J]. APUIS ,2006,114 ( 5 ) :359 - 363.
  • 7Brockbank EC, Ind TE, Barton DP, et al. Preoperative pre- dictors of suboptimal primary surgical cytoreduction in pa- tients with advanced ovarian carcinoma [ J ]. Int J Gynecol Cancer,2004,14 ( 1 ) :42 - 50.
  • 8Dowdy SC, Mullany SA, Brandt KR, et al. The utility of computed to mography seans in predicting suboptimal cy-toreductive surgery in women with adwanced ovarian carci- noma[ J ]. Cancer,2OIM, 101 (2) :346 - 352.
  • 9Qayyum A, Coakley FV, Westphalen AC, et al. Role of CT and MRI imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer[ J]. Gy- necol Onco1,2005,96 (2) :301 - 306.
  • 10Fagotti A, Fanfani F, Ludovisi M, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in ad- vanced ovarian cancer: a pilot study[ J]. Gynecol Oncol, 2005,96 (3) :729 - 735.

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部